Dihydroartemisinin (DHA) - CAS 71939-50-9
Catalog number:
71939-50-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H24O5
Molecular Weight:
284.35
COA:
Inquire
Targets:
Others
Description:
Dihydroartemisinin (DHA) is a semi-synthetic derivative of artemisinin and isolated from the traditional Chinese herb Artemisia annua.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
SM-224, CGP 56696
MSDS:
Inquire
1.Dihydroartemisinin attenuates lipopolysaccharide-induced osteoclastogenesis and bone loss via the mitochondria-dependent apoptosis pathway.
Dou C1,2, Ding N1, Xing J1, Zhao C2, Kang F2, Hou T1, Quan H2, Chen Y2, Dai Q1, Luo F1, Xu J1, Dong S2,3. Cell Death Dis. 2016 Mar 31;7:e2162. doi: 10.1038/cddis.2016.69.
Dihydroartemisinin (DHA) is a widely used antimalarial drug isolated from the plant Artemisia annua. Recent studies suggested that DHA has antitumor effects utilizing its reactive oxygen species (ROS) yielding mechanism. Here, we reported that DHA is inhibitory on lipopolysaccharide (LPS)-induced osteoclast (OC) differentiation, fusion and bone-resorption activity in vitro. Intracellular ROS detection revealed that DHA could remarkably increase ROS accumulation during LPS-induced osteoclastogenesis. Moreover, cell apoptosis was also increased by DHA treatment. We found that DHA-activated caspase-3 increased Bax/Bcl-2 ratio during LPS-induced osteoclastogenesis. Meanwhile, the translocation of apoptotic inducing factor (AIF) and the release of cytochrome c from the mitochondria into the cytosol were observed, indicating that ROS-mediated mitochondrial dysfunction is crucial in DHA-induced apoptosis during LPS-induced osteoclastogenesis. In vivo study showed that DHA treatment decreased OC number, prevents bone loss, rescues bone microarchitecture and restores bone strength in LPS-induced bone-loss mouse model.
2.Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells.
Huang Z, Huang X, Jiang D, Zhang Y, Huang B, Luo G1. J Cancer Res Ther. 2016 Jan-Mar;12(1):244-7. doi: 10.4103/0973-1482.151855.
CONTEXT: Dihydroartemisinin (DHA) exhibits anticancer activity in a number of human cancer cells. However, it is still unknown whether DHA has anticancer effect on nasopharyngeal cancer (NPC) cells.
3.Dihydroartemisinin alleviates bile duct ligation-induced liver fibrosis and hepatic stellate cell activation by interfering with the PDGF-βR/ERK signaling pathway.
Chen Q1, Chen L1, Kong D2, Shao J1, Wu L1, Zheng S3. Int Immunopharmacol. 2016 May;34:250-8. doi: 10.1016/j.intimp.2016.03.011.
Liver fibrosis represents a frequent event following chronic insult to trigger wound healing responses in the liver. Activation of hepatic stellate cells (HSCs), which is a pivotal event during liver fibrogenesis, is accompanied by enhanced expressions of a series of marker proteins and pro-fibrogenic signaling molecules. Artemisinin, a powerful antimalarial medicine, is extracted from the Chinese herb Artemisia annua L., and can inhibit the proliferation of cancer cells. Dihydroartemisinin (DHA), the major active metabolite of artemisinin, is able to attenuate lung injury and fibrosis. However, the effect of DHA on liver fibrosis remains unclear. The aim of this study was to investigate the effect of DHA on bile duct ligation-induced injury and fibrosis in rats. DHA improved the liver histological architecture and attenuated collagen deposition in the fibrotic rat liver. Experiments in vitro showed that DHA inhibited the proliferation of HSCs and arrested the cell cycle at the S checkpoint by altering several cell-cycle regulatory proteins.
4.Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells.
Huang Z, Huang X, Jiang D, Zhang Y, Huang B, Luo G1. J Cancer Res Ther. 2016 Jan-Mar;12(1):244-7. doi: 10.4103/0973-1482.151855.
CONTEXT: Dihydroartemisinin (DHA) exhibits anticancer activity in a number of human cancer cells. However, it is still unknown whether DHA has anticancer effect on nasopharyngeal cancer (NPC) cells.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1323403-33-3 Iberdomide

Iberdomide
(CAS: 1323403-33-3)

Iberdomide, also known as CC-220, is a modulator of cereblon potentially for the treatment of systemic lupus erythematosus. Iberdomide exhibits an IC50 of 60 nM...

CAS 58186-27-9 Idebenone

Idebenone
(CAS: 58186-27-9)

Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.

CAS 130495-35-1 SKF-96365

SKF-96365
(CAS: 130495-35-1)

SKF-96365, a store-operated Ca2+ entry inhibitor, has been found to restrain the depolarization of circular smooth muscle caused by acetylcholine and also exhib...

CAS 872178-65-9 Rabeximod

Rabeximod
(CAS: 872178-65-9)

Rabeximod is an immunomodulator agent. It can suppress arthritis by preventing activation of inflammatory cells, most likely macrophages, in a time dependent fa...

CAS 18059-10-4 Peiminine

Peiminine
(CAS: 18059-10-4)

Peiminine and DXS significantly reduced alveolar inflammation and pulmonary interstitial inflammation in rats with bleomycin-induced lung injury. peiminine inhi...

ARQ 736
(CAS: 1228237-47-5)

CAS 78-28-4 Emylcamate

Emylcamate
(CAS: 78-28-4)

Emylcamateis an anxiolytic and muscle relaxant. It can be used for the treatment of anxiety and tension.

CAS 95734-82-0 Nedaplatin

Nedaplatin
(CAS: 95734-82-0)

Nedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.

CAS 25301-02-4 Tyloxapol

Tyloxapol
(CAS: 25301-02-4)

Tyloxapol, a nonionic liquid polymer, is a surfactant to aid liquefaction.

CAS 86170-12-9 CGP 23996

CGP 23996
(CAS: 86170-12-9)

CGP 23996 is a non-reducible somatostatin analog. It can be used for autoradiography.

Amidantel hydrochloride
(CAS: 69884-15-7)

Amidantel is a potent anthelminthic agent.

CAS 50264-69-2 Lonidamine

Lonidamine
(CAS: 50264-69-2)

Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhan...

CAS 29053-27-8 Meseclazone

Meseclazone
(CAS: 29053-27-8)

Meseclazone, a nonsteroidal anti-inflammatory drug (NSAID), exhibits inhibitory potency of secondary phase ADP aggregation.

CAS 1115-70-4 Metformin HCl

Metformin HCl
(CAS: 1115-70-4)

Metformin decreases hyperglycemia primarily by suppressing glucose production by the liver (hepatic gluconeogenesis).

CAS 1021-11-0 Guanoxyfen sulfate

Guanoxyfen sulfate
(CAS: 1021-11-0)

Guanoxyfen sulfate is an inhibitor of vasoconstrictor responses to sympathetic nerve stimulation. It could potentiate the actions of adrenaline and noradrenalin...

EL-102
(CAS: 1233948-61-2)

EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 2...

CI 972
(CAS: 115787-68-3)

This active molecular is a potent purine nucleoside phosphorylase inhibitor and a T cell-selective immunosuppressive agent. CI-972 inhibited proliferation of hu...

CAS 113240-27-0 Cgp 29030A

Cgp 29030A
(CAS: 113240-27-0)

This molecular is a piperazine derivative and its Pharmacological activity probablely is inhibition on nociceptive dorsal horn neurons that processed input from...

CAS 13647-35-3 Trilostane

Trilostane
(CAS: 13647-35-3)

Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing’s syndrome.

CAS 269730-03-2 RPI-1

RPI-1
(CAS: 269730-03-2)

RPI-1 is a cell-permeable, ATP-dependent RET kinase inhibitor. Oral treatment with RPI-1 caused growth arrest or regression in 81% treated tumors. It can also b...

Chemical Structure

CAS 71939-50-9 Dihydroartemisinin (DHA)

Quick Inquiry

Verification code

Featured Items